Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10286171" target="_blank" >RIV/00216208:11110/14:10286171 - isvavai.cz</a>
Alternative codes found
RIV/00064165:_____/14:10286171
Result on the web
<a href="http://dx.doi.org/10.1056/NEJMoa1316158" target="_blank" >http://dx.doi.org/10.1056/NEJMoa1316158</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1056/NEJMoa1316158" target="_blank" >10.1056/NEJMoa1316158</a>
Alternative languages
Result language
angličtina
Original language name
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Original language description
Somatostatin analogues are commonly used to treat symptoms associated with hormone hypersecretion in neuroendocrine tumors; however, data on their antitumor effects are limited. Lanreotide was associated with significantly prolonged progression-free survival among patients with metastatic enteropancreatic neuroendocrine tumors of grade 1 or 2.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
New England Journal of Medicine
ISSN
0028-4793
e-ISSN
—
Volume of the periodical
371
Issue of the periodical within the volume
3
Country of publishing house
US - UNITED STATES
Number of pages
10
Pages from-to
224-233
UT code for WoS article
000338999800006
EID of the result in the Scopus database
—